Effect of Moclobemide, a New Reversible Monoamine Oxidase Inhibitor, on Absorption and Pressor Effect of Tyramine

Korn, A; Prada, M. Da; Raffesberg, Wolfgang; Gasić, S; Eichler, Hans‐Georg

doi:10.1097/00005344-198801000-00003

Cited by 49 publications

(28 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With regard to other haemodynamic effects of tyramine, there still exists some controversy in the literature about the effects on diastolic blood pressure, some studies reporting no effects (Colombo et al, 1988) and others a slight increase (Korn et al, 1988). We found a slight increase in the present study, the increase in diastolic pressure being 5-7 mm Hg when the corresponding increase in systolic pressure was 30-32 mm Hg.…”

Section: Discussioncontrasting

confidence: 49%

See 1 more Smart Citation

COMT inhibition with nitecapone does not affect the tyramine pressor response.

Sundberg

Gordin

1991

Brit J Clinical Pharma

View full text Add to dashboard Cite

Nitecapone (OR-462) is a new selective COMT inhibitor with gastroprotective properties. The aim of the present study was to determine whether nitecapone potentiates the haemodynamic effects of a tyramine-induced increase in catecholamine release. The systolic blood pressure response to tyramine was studied in 11 healthy male volunteers (age 20-32 years). Tyramine was given i.v. as rapid bolus injections in increasing doses without drug intake and after oral intake of single doses of 25 mg and 100 mg of nitecapone. The tyramine dose required to increase systolic blood pressure by 30 mm Hg ('pressor dose') was 4.98 mg, 5.04 mg and 4.88 mg after no medication, and with 25 mg and 100 mg of nitecapone, respectively: There were also no differences in the systolic blood pressure response vs time curves between the three regimens. COMT inhibition with nitecapone did not potentiate the haemodynamic responses to tyramine-induced catecholamine release.

show abstract

Section: Discussioncontrasting

confidence: 49%

“…The tyramine pressor response test has been extensively used to evaluate the pressor effect of drugs interfering with catecholamine metabolism (Colombo et al, 1988;Korn et al, 1988;Pickar et al, 1981).…”

Section: Discussionmentioning

confidence: 99%

COMT inhibition with nitecapone does not affect the tyramine pressor response.

Sundberg

Gordin

1991

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…The safer transdermal selegiline (Barrett et al, 1997) and reversible MAOIs, such as moclobemide (Korn et al, 1987), should be considered for patients with atypical depression, especially in depressed adolescents.…”

Section: Discussionmentioning

confidence: 99%

DSM-IV Depression with Atypical Features: Is It Valid?

Stewart

McGrath

Quitkin³

et al. 2009

Neuropsychopharmacol

View full text Add to dashboard Cite

Atypical features were incorporated into the American Psychiatric Association's Diagnostic and Statistical Manual, Fourth Edition (DSM-IV, 1994) as an illness specifier for major depression and dysthymia. The validity of depression with atypical features was supported by differences relative to depression with melancholic features in syndromal symptoms, course of illness, biology, family history, and treatment response. This paper reviews post-DSM-IV literature relevant to the validity of depression with atypical features. Most studies support the pre-DSM-IV findings. Again, course of illness, biological, family, and treatment differences are shown between melancholia and depression with atypical features. Several biologic studies report nondepressed controls have mean values between depressed subjects having atypical features and other depressed patients. This suggests atypical depression is a distinct depressive group rather than a milder form of melancholia. In addition, some studies show distinctions between depressed subjects with atypical features and those having neither atypical nor melancholic features. As depression with atypical features separates not only from melancholia but also from other depressed groups and controls over a range of meaningful distinctions, we conclude it is a valid clinical syndrome, useful both heuristically and in driving treatment decisions.

show abstract

“…Moclobemide penetrates well the brain, maximal concentrations of moclobemide in CSF are reached 2 h after oral administration and high CSF/plasma ratio (0.5) can be obtained (Lauy et al, 1990). Non-selective MAOIs interact with tyramine to raise blood pressure but this interaction is negligible with moclobemide (Berlin et al, 1989;Korn et al, 1988).…”

Section: Introductionmentioning

confidence: 99%

Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase‐A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.

Berlin

Zimmer

et al. 1990

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 The effects of two reversible, predominantly monoamine oxidase-A (MAO-A) inhibitors, moclobemide (150 mg three times daily) and toloxatone (400-200-400 mg day-1) on monoamine metabolites and psychometric performance were compared in a double-blind placebo controlled crossover study in 12 healthy subjects. 2 After 7 days of moclobemide/toloxatone/placebo administration subjects were hospitalized for 24 h on day 8. Blood samples were drawn every 2 h for determination of plasma noradrenaline (NA), 3,4-dihydroxyphenylglycol (DHPG), homovanillic acid (HVA) and 5-hydroxyindolacetic acid (5-HIAA). Urine was collected for measurements of normetanephrine and 3-methoxytyramine excretion. Psychometric performance (short-and long-term memory, critical flicker fusion frequency, choice reaction time) and subjective feelings were assessed before each drug intake (in the morning, at noon, in the evening). 3 Compared with placebo, both reversible monoamine oxidase inhibitors decreased the plasma concentration of DHPG and HVA. The overall fall in DHPG (AUC from 0 to 24 h) was 44% during moclobemide and 12% during toloxatone (P < 0.001) and the overall decrease in HVA was 38% and 20% (P < 0.005) on moclobemide and toloxatone, respectively. 4 Before the next drug intake, MAO-A inhibition, as judged by the decrease of plasma DHPG concentration, was significantly different from placebo with moclobemide but not with toloxatone. 5 Moclobemide, but not toloxatone, exerted a moderate, but significant inhibition of the deamination of 5-hydroxytryptamine (5-HT) as judged by the fall in plasma 5-HIAA concentration. Neither drug influenced plasma NA concentration. 6 A significant rise in urinary excretion of normetanephrine was observed on moclobemide and to a lesser extent on toloxatone. The urinary excretion of 3-methoxytyramine was significantly raised by moclobemide but not by toloxatone. 7 Neither moclobemide nor toloxatone altered memory function, vigilance, subjective feelings or sleep characteristics of the subjects.

show abstract

Effect of Moclobemide, a New Reversible Monoamine Oxidase Inhibitor, on Absorption and Pressor Effect of Tyramine

Cited by 49 publications

References 0 publications

COMT inhibition with nitecapone does not affect the tyramine pressor response.

COMT inhibition with nitecapone does not affect the tyramine pressor response.

DSM-IV Depression with Atypical Features: Is It Valid?

Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase‐A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.

Contact Info

Product

Resources

About